The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Emergence of Adverse Events Following Discontinuation of Treatment With Extended-Release Venlafaxine
Abstract
OBJECTIVE: The rate of adverse events following discontinuation of treatment with extended-release venlafaxine was compared with the rate associated with discontinuation of placebo administration. METHOD: The subjects were 20 outpatients with major depressive disorder who had participated in a multicenter, double-blind, placebo-controlled study of the efficacy of the new extended-release formulation of venlafaxine. RESULTS: During the 3 days after discontinuation of treatment with the study drug, seven (78%) of the nine venlafaxine-treated subjects and two (22%) of the nine placebo-treated patients reported the emergence of adverse events, a statistically significant difference. CONCLUSIONS: These results suggest that clinicians discontinuing venlafaxine treatment should consider tapering the medication dose gradually.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Serotonin Reuptake Inhibitor Withdrawal
Coupland, N. J., Bell, C. J., & Potokar, J. P. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199610000-00003 · Cited by 303
Discontinuation reactions following sertraline
Leiter, F. L., Nierenberg, A. A., Sanders, K. M., & Stern, T. A. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(95)00311-8 · Cited by 40
Self-citation
Cited by
Pharmacologic management of neuropathic pain: Evidence-based recommendations
Dworkin, R. H., O’Connor, A. B., Backonja, M., Farrar, J. T., Finnerup, N. B., Jensen, T. S., Kalso, E. A., Loeser, J. D., Miaskowski, C., Nurmikko, T. J., et al. (2007) · Pain · doi:10.1016/j.pain.2007.08.033 · Cited by 2,126
Brain foods: The effects of nutrients on brain function.
Gómez-Pinilla, F. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2421 · Cited by 1,372
Dworkin, R. H., O'Connor, A. B., Audette, J., Baron, R., Gourlay, G. K., Haanpää, M. L., Kent, J. L., Krane, E. J., LeBel, A. A., Levy, R. M., et al. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0649 · Cited by 1,325
Haroon, E., Raison, C. L., & Miller, A. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.205 · Cited by 1,000
Treatment of neuropathic pain: an overview of recent guidelines.
O'Connor, A. B., & Dworkin, R. H. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.04.007 · Cited by 781
Inflammation Effects on Motivation and Motor Activity: Role of Dopamine
Felger, J. C., & Treadway, M. T. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.143 · Cited by 442
Maldonado, J. R. (2008) · Critical Care Clinics · doi:10.1016/j.ccc.2008.06.004 · Cited by 338
Carney, R. M., Blumenthal, J. A., Freedland, K. E., Youngblood, M., Veith, R. C., Burg, M. M., Cornell, C., Saab, P. G., Kaufmann, P. G., Czajkowski, S. M., et al. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000133362.75075.a6 · Cited by 291
Papakostas, G. I., Shelton, R. C., Zajecka, J. M., Etemad, B., Rickels, K., Clain, A., Baer, L., Dalton, E. D., Sacco, G. R., Schoenfeld, D., et al. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11071114 · Cited by 275
Self-citationThe Homocysteine Hypothesis of Depression
Folstein, M., Liu, T., Peter, I., Buel, J., Arsenault, L., Scott, T., & Qiu, W. W. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.861 · Cited by 262
Consensus paper of the WFSBP Task Force on Biological Markers: Biological Markers in Depression
Mössner, R., Mikova, O., Koutsilieri, E., Saoud, M., Ehlis, A.-C., Müller, N., Fallgatter, A. J., & Riederer, P. (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701263303 · Cited by 254
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214
Montgomery, S. A., Huusom, A. K. T., & Bothmer, J. (2004) · Neuropsychobiology · doi:10.1159/000078225 · Cited by 168
Discontinuation symptoms in depression and anxiety disorders
Baldwin, D. S., Montgomery, S. A., Nil, R., & Lader, M. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006358 · Cited by 140
“, 1993), selective serotonin reuptake inhibitors (SSRIs ; Therrien and Markowitz, 1997), and other antidepressants (Fava et al., 1997).”
BackgroundKaymaz, N., van Os, J., Loonen, A. J. M., & Nolan, W. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0910 · Cited by 135
Sir, A., D'Souza, R. F., Uguz, S., George, T., Vahip, S., Hopwood, M., Martin, A. J., Lam, W., & Burt, T. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1015 · Cited by 129
“Early reports suggest important differences in safety and tolerability, specifically in the impact on blood pressure(7) and adverse events associated with treatment discontinuation.(8,9) The current study was designed to test for differences between sertraline and venlafaxine XR in the treatment of major depressive di…”
MethodVortioxetine: a novel antidepressant for the treatment of major depressive disorder
Gonda, X., Sharma, S. R., & Tarazi, F. I. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1546691 · Cited by 123
Recognising and managing antidepressant discontinuation symptoms
Haddad, P. M., & Anderson, I. M. (2007) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.105.001966 · Cited by 109
Long, S.-J., & Benton, D. (2013) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31827d5fbd · Cited by 110
The reappraisal of benzodiazepines in the treatment of anxiety and related disorders
Starcevic, V. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.963057 · Cited by 90
Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment
Judge, R., Parry, M. G., Quail, D., & Jacobson, J. G. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00002 · Cited by 87
Alpert, M., Silva, R. R., & Pouget, E. R. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000084024.22282.cd · Cited by 72
Nierenberg, A. A., Ostacher, M. J., Huffman, J. C., Ametrano, R. M., Fava, M., & Perlis, R. H. (2008) · Journal of Occupational & Environmental Medicine · doi:10.1097/jom.0b013e31816b5034 · Cited by 70
Self-citationRickels, K., Etemad, B., Khalid-Khan, S., Lohoff, F. W., Rynn, M. A., & Gallop, R. J. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.170 · Cited by 63
Third-Generation Antidepressants: Do They Offer Advantages Over the SSRIs?
Olver, J. S., Burrows, G. D., & Norman, T. R. (2001) · CNS Drugs · doi:10.2165/00023210-200115120-00004 · Cited by 63
Incidence and Nature of Antidepressant Discontinuation Symptoms
Kalfas, M., Tsapekos, D., Butler, M., McCutcheon, R. A., Pillinger, T., Strawbridge, R., Bhat, B. B., Haddad, P. M., Cowen, P. J., Howes, O. D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.1362 · Cited by 42
Is There a Potential of Misuse for Venlafaxine and Bupropion?
Schifano, F., & Chiappini, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00239 · Cited by 38
(2025) · doi:10.1038/s41380-024-02782-4 · Cited by 32
Antidepressant discontinuation (withdrawal) symptoms presenting as ‘stroke’
Haddad, P. M., Devarajan, S., & Dursun, S. M. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500210 · Cited by 25
“In the 3 days following termination of medication, seven (78%) of nine venlafaxine-treated subjects and two (22%) of nine placebo-treated subjects reported the emergence of adverse events in response to open questioning (Fava et al., 1997).”
BackgroundMontgomery, S. A., Fava, M., Padmanabhan, S. K., J. Guico-Pabia, C., & Tourian, K. A. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832fbb5a · Cited by 27
Discontinuation symptoms and psychotropic drugs
Young, A., & Haddad, P. (2000) · The Lancet · doi:10.1016/s0140-6736(05)72262-5 · Cited by 17
Psychotropic discontinuation leading to an NMS‐like condition
Kurien, R., & Vattakatuchery, J. J. (2013) · Progress in Neurology and Psychiatry · doi:10.1002/pnp.297 · Cited by 6
Do discontinuation symptoms predict depression relapse after antidepressant cessation?
Volkmann, C., Abulikemu, S., Berwian, I. M., Huys, Q. J., & Walter, H. (2023) · doi:10.31234/osf.io/fxye5 · Cited by 2
Metadata
- Authors
- Fava, M., Mulroy, R., Alpert, J., Nierenberg, A. A., & Rosenbaum, J. F.
- Venue
- American Journal of Psychiatry
- Published
- 1997-12-01
- Volume
- 154
- Issue
- 12
- Pages
- 1760-1762
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W1986043820
- Cited by
- 198
- References
- 3
- FWCI
- 4.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.